MA45244A - Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 - Google Patents
Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1Info
- Publication number
- MA45244A MA45244A MA045244A MA45244A MA45244A MA 45244 A MA45244 A MA 45244A MA 045244 A MA045244 A MA 045244A MA 45244 A MA45244 A MA 45244A MA 45244 A MA45244 A MA 45244A
- Authority
- MA
- Morocco
- Prior art keywords
- substituted pyridines
- pyridines used
- dnmt1 inhibitors
- dnmt1
- inhibitors
- Prior art date
Links
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 title 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349227P | 2016-06-13 | 2016-06-13 | |
| US201662393256P | 2016-09-12 | 2016-09-12 | |
| US201662412343P | 2016-10-25 | 2016-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45244A true MA45244A (fr) | 2019-04-17 |
Family
ID=59239935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045244A MA45244A (fr) | 2016-06-13 | 2017-06-13 | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10975056B2 (enExample) |
| EP (1) | EP3468953B1 (enExample) |
| JP (1) | JP7051829B2 (enExample) |
| KR (1) | KR20190017030A (enExample) |
| CN (1) | CN109563043B (enExample) |
| AU (1) | AU2017283790B2 (enExample) |
| CA (2) | CA3026211A1 (enExample) |
| CL (1) | CL2018003577A1 (enExample) |
| CO (1) | CO2018013717A2 (enExample) |
| CR (1) | CR20180580A (enExample) |
| DO (1) | DOP2018000273A (enExample) |
| ES (1) | ES2993451T3 (enExample) |
| IL (1) | IL263163B (enExample) |
| JO (1) | JOP20180120A1 (enExample) |
| MA (1) | MA45244A (enExample) |
| MX (1) | MX391600B (enExample) |
| PE (1) | PE20190971A1 (enExample) |
| PH (1) | PH12018502633B1 (enExample) |
| SG (1) | SG11201809559UA (enExample) |
| WO (2) | WO2017216727A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MA42608A (fr) | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| RS62410B1 (sr) | 2016-10-04 | 2021-10-29 | Merck Sharp & Dohme | Benzo[b]tiofenska jedinjenja kao agonisti sting |
| EP4424364B1 (en) | 2017-03-28 | 2026-01-21 | Gilead Sciences, Inc. | Combinations for use in the treatment of cirrhosis and liver fibrosis |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| WO2019027857A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| CN109651358B (zh) * | 2017-10-11 | 2023-04-07 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| WO2019195124A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
| WO2019195063A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| PE20211907A1 (es) | 2019-01-15 | 2021-09-28 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| KR102725082B1 (ko) | 2019-02-19 | 2024-11-04 | 길리애드 사이언시즈, 인코포레이티드 | Fxr 효능제의 고체 형태 |
| CN111662283B (zh) * | 2019-03-07 | 2021-11-16 | 湖南化工研究院有限公司 | 咪唑并吡啶类化合物及其中间体、制备方法与应用 |
| WO2022076563A1 (en) * | 2020-10-07 | 2022-04-14 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
| CN116917273A (zh) * | 2021-03-02 | 2023-10-20 | 葛兰素史克知识产权发展有限公司 | 作为dnmt1抑制剂的经取代的吡啶 |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| CN113278021B (zh) * | 2021-05-29 | 2022-09-23 | 天津全和诚科技有限责任公司 | 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法 |
| JP2024539267A (ja) | 2021-10-19 | 2024-10-28 | アキラバイオ， インコーポレイテッド | ２’－デオキシシチジンアナログを含む組成物、ならびに鎌状赤血球症、サラセミアおよびがんを処置するためのその使用 |
| CN114230459A (zh) * | 2021-12-10 | 2022-03-25 | 武汉九州钰民医药科技有限公司 | 一种化合物的制备方法及分析检测方法 |
| WO2023192629A1 (en) * | 2022-04-01 | 2023-10-05 | Herophilus, Inc. | Induction of mecp2 expression by dna methyl transferase inhibitors |
| WO2024156288A1 (en) * | 2023-01-29 | 2024-08-02 | Shanghai Kygent Pharmaceutical Co., Ltd | Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications |
| CN121368481A (zh) * | 2023-06-29 | 2026-01-20 | 丹娜-法伯癌症研究院 | 用于降解dna甲基转移酶1 (dnmt1)的蛋白水解靶向嵌合体(protacs)的合成和体外表征 |
| WO2025085756A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
| WO2025190285A1 (en) * | 2024-03-12 | 2025-09-18 | Shanghai Kygent Pharmaceutical Co., Ltd | Pyridine compounds, pharmaceutical compositions, and applications |
| CN119306700A (zh) * | 2024-08-28 | 2025-01-14 | 山东大学 | Dnmt1-hdac双靶点抑制剂及其制备方法和应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2030875C (en) | 1990-11-26 | 2002-07-02 | Alan R.P. Paterson | Methods and probes for detecting nucleoside transporter and method for producing the probes |
| CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
| WO1994022853A1 (en) | 1993-03-26 | 1994-10-13 | Shell Internationale Research Maatschappij B.V. | Herbicidal 1-heteroaryl pyrazolidin-3,5-diones |
| KR19990076876A (ko) | 1995-12-29 | 1999-10-25 | 스티븐 베네티아너 | 비트로넥틴 수용체 길항제 |
| AU1295597A (en) | 1995-12-29 | 1997-07-28 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| DE19947154A1 (de) | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| WO2001044172A1 (en) | 1999-12-15 | 2001-06-21 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease and factor xa inhibitors |
| US6794506B2 (en) | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| US20030166554A1 (en) | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10134481A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| TW200406370A (en) | 2002-06-28 | 2004-05-01 | Syngenta Participations Ag | 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives |
| AR043048A1 (es) | 2002-08-30 | 2005-07-13 | Syngenta Participations Ag | Derivados de 4-(3,3-dihalo- aliloxi) fenol con propiedades pesticidas |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| TW200410632A (en) | 2002-12-11 | 2004-07-01 | Syngenta Participations Ag | Dihalo-allyloxy-phenol derivatives having pesticidal activity |
| SE0203712D0 (sv) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
| JP4895806B2 (ja) | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| ATE556067T1 (de) | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
| CA2539707C (en) | 2003-09-23 | 2011-08-09 | Merck & Co., Inc. | Quinoline potassium channel inhibitors |
| AU2011253934C1 (en) | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| EP1655296A1 (en) | 2004-10-25 | 2006-05-10 | Graffinity Pharmaceuticals AG | Thrombin inhibitors |
| EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007148738A1 (ja) | 2006-06-20 | 2007-12-27 | Ishihara Sangyo Kaisha, Ltd. | 新規なピリジル－メタナミン誘導体又はその塩を含有する有害生物防除剤 |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| ATE487720T1 (de) | 2007-02-01 | 2010-11-15 | Astrazeneca Ab | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| WO2009034433A2 (en) | 2007-09-10 | 2009-03-19 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| CA2700783C (en) | 2007-10-08 | 2015-03-17 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| TW201028381A (en) * | 2008-07-14 | 2010-08-01 | Shionogi & Co | Pyridine derivative having ttk inhibition activity |
| TW201011017A (en) | 2008-08-19 | 2010-03-16 | Astrazeneca Ab | Chemical compounds 495-1 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| KR101146010B1 (ko) * | 2009-09-10 | 2012-05-16 | 서울대학교산학협력단 | ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물 |
| CN102686584A (zh) | 2009-11-13 | 2012-09-19 | 盐野义制药株式会社 | 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物 |
| US8563539B2 (en) | 2009-12-23 | 2013-10-22 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| AU2010333804B2 (en) | 2009-12-23 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| US9073903B2 (en) | 2010-02-17 | 2015-07-07 | Jasco Pharmaceuticals, LLC | Imidazole-2,4-dione inhibitors of casein kinase 1 |
| JP5911476B2 (ja) | 2010-05-26 | 2016-04-27 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
| WO2012040636A2 (en) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| JP6106605B2 (ja) | 2011-01-17 | 2017-04-05 | カリオファーム セラピューティクス，インコーポレイテッド | オレフィン含有核輸送調節剤およびその使用 |
| WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US20140155419A1 (en) | 2011-07-29 | 2014-06-05 | Erkan Baloglu | Compounds and methods |
| EP2747560A4 (en) | 2011-07-29 | 2015-02-25 | Tempero Pharmaceuticals Inc | CONNECTIONS AND METHODS |
| EP2771012A4 (en) | 2011-10-24 | 2015-06-24 | Glaxosmithkline Ip No 2 Ltd | NEW CONNECTIONS |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| MX372736B (es) | 2012-09-28 | 2020-06-19 | Cancer Research Tech Ltd | Inhibidores de azaquinazolina de la proteina quinasa c atipica. |
| JP2017502970A (ja) | 2014-01-21 | 2017-01-26 | ウォックハート リミテッド | 窒素含有化合物及びその使用 |
| WO2015110999A1 (en) | 2014-01-24 | 2015-07-30 | Piramal Enterprises Limited | Ezh2 inhibitors and uses thereof |
-
2017
- 2017-06-13 ES ES17733902T patent/ES2993451T3/es active Active
- 2017-06-13 WO PCT/IB2017/053511 patent/WO2017216727A1/en not_active Ceased
- 2017-06-13 JP JP2019517187A patent/JP7051829B2/ja active Active
- 2017-06-13 SG SG11201809559UA patent/SG11201809559UA/en unknown
- 2017-06-13 MA MA045244A patent/MA45244A/fr unknown
- 2017-06-13 KR KR1020197000766A patent/KR20190017030A/ko not_active Ceased
- 2017-06-13 EP EP17733902.5A patent/EP3468953B1/en active Active
- 2017-06-13 MX MX2018015483A patent/MX391600B/es unknown
- 2017-06-13 CA CA3026211A patent/CA3026211A1/en active Pending
- 2017-06-13 AU AU2017283790A patent/AU2017283790B2/en not_active Ceased
- 2017-06-13 CA CA3026226A patent/CA3026226A1/en not_active Abandoned
- 2017-06-13 CN CN201780036908.XA patent/CN109563043B/zh active Active
- 2017-06-13 US US16/309,121 patent/US10975056B2/en active Active
- 2017-06-13 PE PE2018003216A patent/PE20190971A1/es unknown
- 2017-06-13 CR CR20180580A patent/CR20180580A/es unknown
- 2017-06-13 WO PCT/IB2017/053509 patent/WO2017216726A1/en not_active Ceased
- 2017-06-13 PH PH1/2018/502633A patent/PH12018502633B1/en unknown
-
2018
- 2018-11-21 IL IL263163A patent/IL263163B/en unknown
- 2018-12-07 DO DO2018000273A patent/DOP2018000273A/es unknown
- 2018-12-10 JO JOP/2018/0120A patent/JOP20180120A1/ar unknown
- 2018-12-12 CL CL2018003577A patent/CL2018003577A1/es unknown
- 2018-12-18 CO CONC2018/0013717A patent/CO2018013717A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20190971A1 (es) | 2019-07-09 |
| CN109563043B (zh) | 2022-05-31 |
| JP2019517596A (ja) | 2019-06-24 |
| CO2018013717A2 (es) | 2019-01-18 |
| EP3468953C0 (en) | 2024-05-22 |
| IL263163A (en) | 2018-12-31 |
| WO2017216726A1 (en) | 2017-12-21 |
| PH12018502633A1 (en) | 2019-09-30 |
| CL2018003577A1 (es) | 2019-04-05 |
| JP7051829B2 (ja) | 2022-04-11 |
| US20190194166A1 (en) | 2019-06-27 |
| KR20190017030A (ko) | 2019-02-19 |
| JOP20180120A1 (ar) | 2019-01-30 |
| DOP2018000273A (es) | 2019-03-31 |
| CA3026211A1 (en) | 2017-12-21 |
| CA3026226A1 (en) | 2017-12-21 |
| AU2017283790B2 (en) | 2019-08-29 |
| CN109563043A (zh) | 2019-04-02 |
| ES2993451T3 (en) | 2024-12-30 |
| PH12018502633B1 (en) | 2023-02-01 |
| MX391600B (es) | 2025-03-21 |
| EP3468953A1 (en) | 2019-04-17 |
| EP3468953B1 (en) | 2024-05-22 |
| AU2017283790A1 (en) | 2018-11-22 |
| IL263163B (en) | 2021-10-31 |
| US10975056B2 (en) | 2021-04-13 |
| SG11201809559UA (en) | 2018-12-28 |
| CR20180580A (es) | 2019-07-02 |
| WO2017216727A1 (en) | 2017-12-21 |
| MX2018015483A (es) | 2019-03-18 |
| BR112018075992A2 (pt) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| EP3386981A4 (en) | HETEROCYCLES SUITABLE AS ANTICROGEN | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| EP3533787A4 (en) | PYRIDONE COMPOUND AS A C-MET INHIBITOR | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| EP3416964A4 (en) | Carboxamide derivatives as RSK inhibitors | |
| FR25C1047I1 (fr) | Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac |